Home › Psoriatic Arthritis › NCT07290036

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Be 18+ years old and legally able to consent
2. Have active psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), suitable for bimekizumab treatment
3. Weigh between 45-100 kg (females) or 50-100 kg (males).
4. Be biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve or have stopped bDMARDs ≥3 months or 5 half-lives ago

Exclusion Criteria:

1. Serious organ system disorders (e.g., heart, liver, kidney, gastrointestinal, neuro)
2. Severe psychiatric issues or substance abuse in the past year
3. Recent or chronic infections, including tuberculosis (TB) or nontuberculous mycobacterium (NTMB)
4. Other inflammatory diseases (e.g., rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD))
5. Recent live vaccines (within 8 weeks) or Bacillus Calmette-Guerin (BCG) (within 1 year)
6. Recent use of glucagon-like peptide-1 (GLP-1) agonists (within 28 weeks)

About the study

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

What is being tested

• Bimekizumab regimen 1 iv (drug)
• Bimekizumab regimen 2 iv (drug)
• Bimekizumab regimen 3 sc (drug)

Sponsor: UCB Biopharma SRL · Participants: 392 · Started: Dec 10, 2025

Contact the study team

• UCB Cares · Phone: +18445992273
• UCB Cares · Phone: +18445992273

Official record on ClinicalTrials.gov — NCT07290036

Locations in the U.S.

Conditions

• Psoriatic Arthritis

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.